



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	10/633,630	
	<b>Filing Date</b>	August 5, 2003	
	<b>First Named Inventor</b>	Klaus GIESE et al.	
	<b>Group Art Unit</b>	1645	
	<b>Examiner Name</b>	Unassigned	
<b>Total Number of Pages in This Submission</b>		<b>Attorney Docket Number</b>	39078-0005

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Response  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Form SB/08A (w/19 references)</b>
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Paul M. Boon, Reg. No. 40,244, Customer No. 26633
Signature	
Date	March 5, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 39078-0005

Applicant: Klaus GIESE et al.

Confirmation No. 6369

Appl. No.: 10/633,630

Examiner: Unassigned

Filing Date: August 5, 2003

Art Unit: 1645

Title: INTERFERING RNA MOLECULES

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

**RELEVANCE STATEMENT**

The relevance of the documents are described in the present specification.

**TIMING/FEE**

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date:

March 5, 2004


By



**Customer No. 26633**  
**HELLER EHRMAN WHITE &**  
**MCAULIFFE**  
1666 K Street, N.W., Suite 300  
Washington, DC 20006  
Telephone: (202) 912-2142  
Facsimile: (202) 912-2020

Paul M. Booth  
Attorney for Applicant  
Registration No. 40,244

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

## **Complete if Known**

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE et al.
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	39078-0005

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A01	ROBERT BARSTEAD, "Genome-wide RNAi", Current Opinion in Chemical Biology, 2001, pp. 63-66, Vol. 5	
	A02	DAVID C. BAULCOMBE, "Fast forward genetics based on virus-induced gene silencing", Current Opinion in Plant Biology, 1999, pp. 109-113, Vol. 2	
	A03	EMILY BERNSTEIN et al., "Role for a bidentate ribonuclease in the initiation step of RNA interference", Nature, January 18, 2001, p. 363-366, Vol. 409	
	A04	ERIC BILLY et al., "Specific Interference with Gene Expression Induced by Long, Double-Stranded RNA in Mouse Embryonal Teratocarcinoma Cell Lines", Proceedings of the National Academy of Sciences of the United States of America, Dec. 4, 2001, pp. 14428-14433, Vol. 98, No. 25	
	A05	CHRISTIAN CAZENAVE et al., "Rate of degradation of [α]- and [β]-oligodeoxynucleotides in Xenopus oocytes. Implications for anti-messenger strategies", Nucleic Acids Research, 1987, pp. 10507-10521, Vol. 15, No. 24	
	A06	SAYDA M. ELBASHIR et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", Nature, May 24, 2001, pp 494-498, Vol. 411	
	A07	ANDREW FIRE, "RNA-triggered gene silencing", TIG, September 1999, pp. 358-363, Vol. 15, No. 9	
	A08	JASON R. KENNERDELL et al., "Heritable gene silencing in Drosophila using double-stranded RNA", Nature Biotechnology, July 2000, pp. 896-898, Vol. 17	
	A09	JASON R. KENNERDELL et al., "Use of dsRNA-Mediated Genetic Interference to Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway", Cell, December 23, 1998, pp. 1017-1026, Vol. 95	
	A10	STUART K. KIM, "Functional genomics: The worm scores a knockout", Current Biology, 2001, pp. R85-R87, Vol. 11	
	A11	IKUMA MAEDA et al., "Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi", Current Biology, 2001, pp. 171-176, Vol. 11	
	A12	MARY K. MONTGOMERY et al., "RNA as a Target of Double-Stranded RNA-Mediated Genetic Interference in Caenorhabditis elegans", Proceedings of the National Academy of Sciences of the United States of America, Dec. 22, 1998, pp. 15502-15507, Vol. 95, No. 26	
	A13	ANTTI NYKÄNEN et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway", Cell, November 2, 2001, pp. 309-321, Vol. 107	
	A14	PHILLIP A. SHARP, "RNA interference-2001", Genes & Development, 2001, pp. 485-490, Vol. 15	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE et al.
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	39078-0005

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A15	MARIA STERNBERGER et al., "GeneBlocs Are Powerful Tools to Study and Delineate Signal Transduction Processes That Regulate Cell Growth and Transformation", Antisense & Nucleic Acid Drug Development, 2002, pp. 131-143, Vol. 12	
	A16	THOMAS TUSCHL et al., "Targeted mRNA degradation by double-stranded RNA in vitro", Genes & Development, 1999, pp. 3191-3197, Vol. 13	
	A17	PETER M. WATERHOUSE et al., "Gene silencing as an adaptive defense against viruses", Nature, June 14, 2001, pp. 834-842, Vol. 411	
	A18	FLORENCE WIANNY et al., "Specific interference with gene function by double-stranded RNA in early mouse development", Nature Cell Biology, February 2000, pp. 70-75, Vol. 2	
	A19	ERIC WICKSTROM, "Oligodeoxynucleotide stability in subcellular extracts and culture media", Journal of Biochemical and Biophysical Methods, 1986, pp. 97-102, Vol. 13	

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

→